EAM
Erste Asset Management Portfolio holdings
AUM
$11.9B
1-Year Return
22.95%
This Quarter Return
+12.25%
1 Year Return
+22.95%
3 Year Return
+112.82%
5 Year Return
+205.55%
10 Year Return
–
AUM
$7.34B
AUM Growth
+$518M
(+7.6%)
Cap. Flow
-$17.9M
Cap. Flow
% of AUM
-0.24%
Top 10 Holdings %
Top 10 Hldgs %
23.18%
Holding
927
New
39
Increased
180
Reduced
133
Closed
52
Top Buys
| 1 |
AutoZone
AZO
|
+$50.4M |
| 2 |
Apple
AAPL
|
+$33.1M |
| 3 |
Masimo
MASI
|
+$16.9M |
| 4 |
NOVA
Sunnova Energy
NOVA
|
+$16.1M |
| 5 |
Pure Storage
PSTG
|
+$13M |
Top Sells
| 1 |
NVIDIA
NVDA
|
+$52.8M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$19.8M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$18.9M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$16.8M |
| 5 |
Texas Roadhouse
TXRH
|
+$16.6M |
Sector Composition
| 1 | Technology | 34.21% |
| 2 | Healthcare | 16.51% |
| 3 | Consumer Discretionary | 10.4% |
| 4 | Financials | 10.05% |
| 5 | Industrials | 9.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
Ascendis Pharma
ASND
$12.3B
| $2.75M | 0.04% |
18,500
| – | – |
|
277
Workday
WDAY
$61.6B
| $2.74M | 0.04% |
10,000
| – | – |
|
278
Biohaven
BHVN
$1.53B
| $2.67M | 0.04% |
46,900
+19,000
| +68% | +$1.08M |
|
279
Roivant Sciences
ROIV
$9.21B
| $2.67M | 0.04% |
246,000
| – | – |
|
280
Omega Healthcare
OHI
$12.6B
| $2.6M | 0.04% |
83,576
+3,066
| +4% | +$95.2K |
|
281
Viking Therapeutics
VKTX
$2.84B
| $2.58M | 0.04% |
31,000
-49,000
| -61% | -$4.08M |
|
282
Unity
U
$19.2B
| $2.57M | 0.03% |
96,120
-220,000
| -70% | -$5.87M |
|
283
Apellis Pharmaceuticals
APLS
$3.39B
| $2.46M | 0.03% |
42,000
| – | – |
|
284
Welltower
WELL
$113B
| $2.42M | 0.03% |
26,100
+9,000
| +53% | +$836K |
|
285
Tenaris
TS
$18.3B
| $2.39M | 0.03% |
60,000
| – | – |
|
|
BPMC
286
DELISTED
Blueprint Medicines
BPMC
| $2.38M | 0.03% |
25,100
| – | – |
|
287
Repligen
RGEN
$6.68B
| $2.31M | 0.03% |
12,500
| – | – |
|
288
Vaxcyte
PCVX
$4.25B
| $2.3M | 0.03% |
33,600
| – | – |
|
289
Ionis Pharmaceuticals
IONS
$10.3B
| $2.29M | 0.03% |
51,300
| – | – |
|
290
Travelers Companies
TRV
$61.6B
| $2.27M | 0.03% |
9,900
| – | – |
|
291
Ocular Therapeutix
OCUL
$2.22B
| $2.2M | 0.03% |
235,800
| – | – |
|
292
Mondelez International
MDLZ
$81B
| $2.16M | 0.03% |
30,839
+814
| +3% | +$57K |
|
293
Xenon Pharmaceuticals
XENE
$2.89B
| $2.15M | 0.03% |
50,000
| – | – |
|
|
MRO
294
DELISTED
Marathon Oil Corporation
MRO
| $2.14M | 0.03% |
77,184
+7,661
| +11% | +$212K |
|
295
Infosys
INFY
$70.5B
| $2.13M | 0.03% |
120,000
+20,000
| +20% | +$356K |
|
296
Simon Property Group
SPG
$58.6B
| $2.12M | 0.03% |
13,700
+3,000
| +28% | +$464K |
|
297
Enanta Pharmaceuticals
ENTA
$193M
| $2.1M | 0.03% |
120,000
| – | – |
|
298
Cartesian Therapeutics
RNAC
$262M
| $2.09M | 0.03% |
107,070
+2,837
| +3% | +$55.4K |
|
299
Global Payments
GPN
$21.1B
| $2.07M | 0.03% |
15,743
+1,381
| +10% | +$182K |
|
300
Goldman Sachs
GS
$231B
| $2.01M | 0.03% |
4,841
+472
| +11% | +$196K |
|